Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

Interactions between GPR116 and the MuSC niche regulate MuSC quiescence and self-renewal through nuclear B-arrestin1

FY 2022-23

Summary
Skeletal muscle is capable of regeneration after injury thanks in part due to a rare population of specialized cells called 'muscle stem cells'. The importance of these cells in the normal regeneration of skeletal muscle is highlighted in muscle disease, where progressive loss of muscle mass and strength is preceded by a loss in numbers and function of these specialized muscle stem cells. Therefore, new regenerative medicine based therapies to treat muscle disease should target the muscle stem cell - to restore their numbers and rejuvenate their regenerative potential. Knowledge of the molecular pathways that regulate muscle stem cells within the context of muscle regeneration is crucial to the development of new therapeutic strategies to treat muscle disease. Approximately one-third of all drugs provide therapeutic benefit by targeting a large family of drug targets called 'G-Protein Coupled Receptors' (GPCRs), making this family of drug targets exceptionally important in pharmacology and biology. Yet, virtually nothing is known about how these drug targets function in stem cells and in regenerative medicine. I will fill this knowledge gap by identifying new pharmacological targets for regenerative medicine-based therapies targeting muscle disease. We have identified one GPCR that is expressed in muscle stem cells. In our pre-clinical mouse models of aging and muscular dystrophy, we show that this GPCR is required for maintenance of the muscle stem cell pool. I will characterize how this receptor is activated and its downstream signaling pathways. Finally, I will examine how this receptor affects muscle regeneration in mouse models of aging, acute injury, and chronic injury in the mouse model of Duchenne muscular dystrophy. By understanding how GPCRs regulate stem cell activity, I will reveal novel pharmacological targets that will promote muscle stem cell activity to regenerate muscle and advance regenerative medicine-based strategies to treat muscle disease.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
475808
Name
Senechal Charlotte B
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Interactions between GPR116 and the MuSC niche regulate MuSC quiescence and self-renewal through nuclear B-arrestin1
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Adhesion Gpcr; Duchenne Muscular Dystrophy; G-Protein Coupled Receptors; Muscle Stem Cell; Musculoskeletal Regeneration; Stachel Peptides
Abstract
Skeletal muscle is capable of regeneration after injury thanks in part due to a rare population of specialized cells called 'muscle stem cells'. The importance of these cells in the normal regeneration of skeletal muscle is highlighted in muscle disease, where progressive loss of muscle mass and strength is preceded by a loss in numbers and function of these specialized muscle stem cells. Therefore, new regenerative medicine based therapies to treat muscle disease should target the muscle stem cell - to restore their numbers and rejuvenate their regenerative potential. Knowledge of the molecular pathways that regulate muscle stem cells within the context of muscle regeneration is crucial to the development of new therapeutic strategies to treat muscle disease. Approximately one-third of all drugs provide therapeutic benefit by targeting a large family of drug targets called 'G-Protein Coupled Receptors' (GPCRs), making this family of drug targets exceptionally important in pharmacology and biology. Yet, virtually nothing is known about how these drug targets function in stem cells and in regenerative medicine. I will fill this knowledge gap by identifying new pharmacological targets for regenerative medicine-based therapies targeting muscle disease. We have identified one GPCR that is expressed in muscle stem cells. In our pre-clinical mouse models of aging and muscular dystrophy, we show that this GPCR is required for maintenance of the muscle stem cell pool. I will characterize how this receptor is activated and its downstream signaling pathways. Finally, I will examine how this receptor affects muscle regeneration in mouse models of aging, acute injury, and chronic injury in the mouse model of Duchenne muscular dystrophy. By understanding how GPCRs regulate stem cell activity, I will reveal novel pharmacological targets that will promote muscle stem cell activity to regenerate muscle and advance regenerative medicine-based strategies to treat muscle disease.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Senechal, Charlotte B
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2022-23) | Canada Spends